-+ 0.00%
-+ 0.00%
-+ 0.00%

Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel

Benzinga·10/30/2025 12:31:30
Listen to the news

Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console ("SYNC"), 15 milliamp (mA) neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health.